I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

I-Mab (IMAB) will host a webinar on July 8th to discuss Phase 1b data for givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy for first-line, Claudin 18.2-positive, metastatic gastric cancers, following its presentation at ESMO GI on July 2nd. The Phase 1b study (n=17) evaluates givastomig with nivolumab and chemotherapy, building on positive Phase 1 monotherapy data; givastomig is being jointly developed with ABL Bio, excluding Greater China and South Korea.

Analysis

I-Mab (NASDAQ: IMAB) is set to disclose crucial clinical updates for its lead immuno-oncology candidate, givastomig, through a presentation of new Phase 1b combination dose escalation data at the ESMO GI congress on July 2, 2025, followed by an investor webinar featuring a key opinion leader on July 8, 2025. Givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB, is under investigation in a Phase 1b study (n=17) as a first-line treatment for Claudin 18.2-positive metastatic gastric cancers when combined with nivolumab and chemotherapy. The company has highlighted that the dose escalation phase of this trial is complete, and enrollment in the first dose expansion cohort (n=20) concluded ahead of schedule, with the second (n=20) cohort also demonstrating rapid recruitment. This progress follows positive Phase 1 monotherapy results and underscores givastomig's potential as a best-in-class therapeutic, engineered for conditional T-cell activation within the tumor microenvironment with a design aimed at minimizing toxicities common to other 4-1BB targeting agents. The announcement is accompanied by a 'strongly positive' sentiment (overall score 0.7, IMAB-specific 0.85) and an 'optimistic' tone, along with a moderate market impact score of 0.6, indicating significant anticipation for the data, which represents a key near-term catalyst for I-Mab.

Key Decisions for Investors

• Investors should closely monitor the upcoming givastomig Phase 1b data presentation at ESMO GI on July 2nd and the subsequent KOL webinar on July 8th, as these results will be critical for assessing the drug's clinical profile and future potential.
• The reported 'ahead of schedule' enrollment in dose expansion cohorts is a positive operational signal; however, the key valuation driver will be the detailed safety and efficacy outcomes from the (n=17) dose escalation study in combination therapy.
• Given givastomig's description as a potential 'best-in-class' agent for metastatic gastric cancer, the forthcoming data on its safety and efficacy in combination with nivolumab and chemotherapy will be pivotal in de-risking the asset and should be carefully evaluated by investors.